Anastrozole: aromatase inhibition, and why over-suppression is the failure mode

A competitive aromatase inhibitor with a two-day half-life, approved in oncology and used off-label in hormone therapy. The pharmacology is simple; the reason it goes wrong is that the symptoms it is used to treat and the symptoms it causes are the same symptoms.

What it blocks, and how completely

Aromatase is the enzyme that converts androgens to oestrogens — testosterone to estradiol, androstenedione to estrone. It is expressed in adipose tissue, bone, brain, and the gonads, which is why estradiol in men is not a gonadal product so much as a peripheral one. Established clinical use Anastrozole is a non-steroidal competitive inhibitor of that enzyme, and at oncology amounts it suppresses whole-body estradiol production by more than 90%.

That potency is the source of the problem. The amounts used in oncology were chosen to suppress estradiol as completely as possible in postmenopausal women with hormone-receptor-positive breast cancer, where estradiol is the thing driving the disease. Nothing about that goal transfers to a man on hormone therapy whose estradiol is a necessary hormone that has risen more than he wants. The amounts described in the app's rows are a small fraction of the oncology amount for exactly this reason.

The modelled half-life is about two days, so an every-third-day schedule leaves substantial carry-over between doses and the level accumulates for roughly ten days before it settles. A change assessed sooner than that is being assessed before it has finished happening — which is one of the more common ways people end up over-suppressed.

Estradiol is not a side effect to be minimised

Established clinical use In men, estradiol is required for bone mineralisation, and the clearest human evidence for that comes from the rare cases of aromatase deficiency and oestrogen-receptor mutation, where men present with unfused epiphyses and osteopenia despite normal testosterone. Estradiol also contributes materially to libido, to erectile function and to lipid handling. Suppressing it toward zero is not a conservative choice.

Off-label or community practice The clinically important fact for anyone using it is symptom overlap. Low libido, flat mood, joint aches and poor erections are reported both when estradiol is high relative to testosterone and when it is too low. Someone who feels poorly, assumes high estradiol, takes more of an aromatase inhibitor and feels worse has produced exactly the outcome the drug was meant to prevent, and the only thing that distinguishes the two states is a measurement.

That measurement has to be the right one. Standard immunoassay estradiol was designed for the concentrations found in women and is unreliable at male concentrations, where cross-reacting steroids can inflate the result. The sensitive-versus-standard estradiol page covers why the two methods disagree and by how much.

Where the practice is heading

Off-label or community practice Prophylactic use — starting an aromatase inhibitor at the same time as testosterone, before any measurement — has moved from common to discouraged in most published discussion of hormone therapy over the last decade. The reasoning is that most people on physiological amounts do not develop symptomatic estradiol elevation, that the symptom overlap makes self-assessment unreliable, and that the bone and lipid consequences of over-suppression accrue silently.

The alternatives are worth knowing because they are often not mentioned. Reducing the amount of testosterone, or splitting it across more frequent smaller injections, lowers the substrate available for aromatisation and is a first-line adjustment in many protocols. Body composition matters too, since adipose tissue is where much of the conversion happens. An aromatase inhibitor is one option among several rather than the default response to a number.

All of that is a prescribing conversation. This page describes what the literature and clinical practice do; it does not tell anyone with a particular estradiol result to take a particular amount, and anyone experiencing the effects described here should be raising them with the clinician who prescribes for them.

The curve, the accumulation ratio and the peak-to-trough figures have a page of their own: Anastrozole half-life and steady state.

The dosing rows the app records

Established clinical use Reproduced from the app’s reference so you can see what it holds, not as a recommendation. Which row applies to a particular person, if any, is a clinical decision this page does not make — and rows describing supraphysiological or post-cycle use are filtered out before this table is built, so what you see here is a subset.

What the app monitors alongside it

The panel below is the app’s own monitoring note for Anastrozole, verbatim. The analytes in it that have a page here are linked; those pages cover what each one measures, which assay produced it and how to read a trend.

• Sensitive versus standard estradiol
• Total testosterone
• Free versus total testosterone, and the three ways labs get the free number

Drawbacks and risks the app records

From the app's own entry. Note how many of these are consequences of the drug working too well rather than of it failing — that is unusual, and it is the single most useful thing to understand about this compound.

• Over-suppression causes joint pain, low libido, depression, bone loss
• Blunts cardiovascular protection from estrogen
• Lab-guided dosing ONLY — not prophylactic
• Negatively affects lipid profile
• Low E2 symptoms mimic high E2 symptoms

Interaction rules that name Anastrozole

From the app’s interaction data, filtered so no rule naming a compound this site does not publish appears. Not exhaustive, and not a safety clearance: a combination that is not listed is one nobody has documented here, which is not the same as one that is fine. The combination checker has the rest.

Questions people actually ask

Does everyone on testosterone therapy need an aromatase inhibitor?

No, and the direction of practice has been away from routine use. Most people on physiological amounts do not develop symptomatic estradiol elevation. Whether a particular person needs one is a decision made from a sensitive-assay measurement and symptoms together, by a prescriber.

How long before a change shows on labs?

At a two-day half-life the level takes about ten days to settle after a change, and estradiol itself then needs time to re-equilibrate. Drawing sooner measures a system still moving. Most protocols reassess at around six weeks, which also allows symptoms to declare themselves.

Is anastrozole interchangeable with exemestane?

They inhibit the same enzyme by different means — anastrozole competitively and reversibly, exemestane by irreversible inactivation — and their half-lives and metabolic profiles differ. They are not dose-equivalent and results with one do not transfer to the other.

What does over-suppression look like on a panel?

A sensitive-assay estradiol below the lower reference limit, often alongside joint discomfort, low libido and low mood that started after the inhibitor rather than before it. The temporal relationship is the informative part, which is the argument for recording when a change was made rather than reconstructing it later.

Where the load-bearing numbers come from

Named rather than linked. Publisher URLs move, and a citation that resolves to a 404 two years from now is worse than one you can search for by name — every entry below is findable from the title and year alone.